https://scholars.lib.ntu.edu.tw/handle/123456789/467177
Title: | GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma | Authors: | Ho W.-L. Chou C.-H. YUNG-MING JENG MENG-YAO LU YUNG-LI YANG SHIANN-TANG JOU Lin D.-T. HSIU-HAO CHANG Lin K.-H. WEN-MING HSU MIN-CHUAN HUANG |
Issue Date: | 2014 | Publisher: | Impact Journals LLC | Journal Volume: | 5 | Journal Issue: | 23 | Start page/Pages: | 12247-12259 | Source: | Oncotarget | Abstract: | Aberrant expression of the simple mucin-type carbohydrate antigens such as Tn antigen is associated with malignant transformation and cancer progression. N-acetylgalactosaminyltransferase 2 (GALNT2), one of the enzymes that mediate the initial step of mucin-type O-glycosylation, is responsible for forming Tn antigen. GALNT2 is expressed differentially in nervous tissues during mouse embryogenesis; however, the role of GALNT2 in neuroblastoma (NB) remains unclear. Here we showed that increased GALNT2 expression evaluated using immunohistochemistry in NB tumor tissues correlated well with the histological grade of differentiation as well as younger age at diagnosis, early clinical stage, primary tumor originated from the extra-adrenal site, favorable INPC histology, and MYCN non-amplification. Multivariate analysis showed that GALNT2 expression is an independent prognostic factor for better survival for NB patients. GALNT2 overexpression suppressed IGF-1- induced cell growth, migration, and invasion of NB cells, whereas GALNT2 knockdown enhanced these NB phenotypes. Mechanistic investigations demonstrated that GALNT2 overexpression modified O-glycans on IGF-1R, which suppressed IGF-1-triggered IGF- 1R dimerization and subsequent downstream signaling events. Conversely, these properties were reversed by GALNT2 knockdown in NB cells. Our findings suggest that GALNT2 regulates malignant phenotypes of NB cells through the IGF-1R signaling pathway, suggesting a critical role for GALNT2 in the pathogenesis of NB. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920000943&doi=10.18632%2foncotarget.2627&partnerID=40&md5=00d59dd6cbf5ec63f603ac68e7ea5ed3 https://scholars.lib.ntu.edu.tw/handle/123456789/467177 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.2627 | SDG/Keyword: | n acetylgalactosaminyltransferase; n acetylgalactosaminyltransferase 2; somatomedin C receptor; unclassified drug; n acetylgalactosaminyltransferase; polypeptide N-acetylgalactosaminyltransferase; somatomedin C receptor; age; animal experiment; animal model; animal tissue; Article; cancer prognosis; cancer staging; cancer survival; cell growth; cell invasion; controlled study; enzyme activity; female; histopathology; human; human tissue; immunohistochemistry; major clinical study; male; migration inhibition; molecular pathology; mouse; neuroblastoma; nonhuman; protein expression; protein glycosylation; survival prediction; survival rate; tumor differentiation; animal; child; fluorescent antibody technique; gene silencing; genetic transfection; infant; Kaplan Meier method; metabolism; mortality; neuroblastoma; newborn; nude mouse; pathology; phenotype; physiology; preschool child; prognosis; signal transduction; xenograft; Animals; Child; Child, Preschool; Female; Fluorescent Antibody Technique; Gene Knockdown Techniques; Heterografts; Humans; Immunohistochemistry; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; N-Acetylgalactosaminyltransferases; Neuroblastoma; Phenotype; Prognosis; Receptor, IGF Type 1; Signal Transduction; Transfection [SDGs]SDG3 |
Appears in Collections: | 解剖學暨細胞生物學科所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.